CA1322027C

CA1322027C - Method and apparatus for controlling tissue growth with an applied fluctuating magnetic field

Info

Publication number: CA1322027C
Application number: CA000592484A
Authority: CA
Inventors: Abraham R. Liboff; Bruce R. Mcleod; Stephen D. Smith
Original assignee: Life Resonances Inc
Current assignee: Life Resonances Inc
Priority date: 1988-03-23
Filing date: 1989-03-01
Publication date: 1993-09-07
Anticipated expiration: 2010-09-07
Also published as: JPH0211170A; AU625756B2; US4932951A; DE68928090T2; EP0338681B1; DE68928090D1; JPH0440030B2; AU3131989A; ES2102350T3; ATE153864T1; EP0338681A1

Abstract

2716.004 ABSTRACT

An apparatus and method for regulating tissue growth in vivo are provided. The apparatus includes a magnetic field generator and a magnetic field detector for producing a controlled, fluctuating, directionally oriented magnetic field parallel to a predetermined axis projecting through the target tissue. The field detector samples the magnetic flux density along the predetermined access and provides a signal to a microprocessor which determines the average value of the flux density. The applied magnetic field is oscillated at predetermined frequencies to maintain a preselected ratio of frequency to average flux density. This ratio is maintained by adjusting the frequency of the fluctuating magnetic field and/or by adjusting the intensity of the applied magnetic field as the composite magnetic flux density changes in response to changes in the local magnetic field to which the target tissue is subjected.
By maintaining these precise predetermined ratios of frequency to average magnetic flux density, growth characteristics of the target tissue are controlled.

Description

27 1 6.004 METHOD AND APPARATUS FOR CONTROLLING TISSUE
GROWTH WIlH ~pPl,IED FLl~UATl~G ~IAGNETl~ FIELP

FIELD OF TH~ I~VENTIOt~

Thc present i~vention reîates ~enerally to methods and apparatus for controllin~ growth characteristics of li~ing tissuc. Morc spccifically, thc prcse~t inventiOD relates to non-inv~sive techniques îor mediating tissue growth, maintcnance and repair.

~I!ACKGRQUI~ID Q~TH~I~VE~ ol~

Tissue and cell development have been studied e~ctensively to determinc thc mcchanisms by which maturation, maintcoance, and repair occur in living organisms. Generally, devclopment of a cell or tissuc can be considered as a transformatjon from one state or stage to another rclativcly pcrmancut ssatc or condition. Dcvelopment encompasses a wide variety of dcvclopmcntal patterns~ all of which arc characterized by progres~ive and systcmatic transformation of thc cclls or tissue.

~ D maDy instanccs it is desirable to control or alter thc dcvelopment of cclls and tissue i~ vivo to enhancc the quality of 1ifc for higher organisms such as man.
To this cDd, science has ~trugglcd to provide meaos by which thc natural order Or an organism can be maintained or restorod in detianco of tebilitating in3ury, disease or other abnormality. Wbile ~omo prior art tborapies have beeD ~uccessful, others have failed to rcach thcir full potenti~l due to unwanted side cffecls, infcrior results, or difficult implemcntation.

~ s ~ill bc ~ppreciatcd by t~ose skilted in tbe rt, tissuc and 0rgaD
dcvclopment jDVOIVC complcx proces~es of cellular l~rowth, differentiation and interaction mcdia~ed by complex biochcm;cal rcactions. At the geDetic level, devclopment is regulattd by senomic exprcssion; at the cellular Icvel, she role of membrane interaction with the complex biochemical milicu of higher or~anisms is 1- ~

instrumental in developmental processes. Moreover, "remodeling" of tissues or organs is often an essential step in the natural development of higher organisms.
In recent years, multidisciplinary investigations of developmental processes have provided evidence suggesting that electric and magnetic fields play an important role in cell and tissue behaviour. In United States Patent 4,818,697 entitled '~echniques for Enhancing the Permeability of Ions through Membranes", a method and apparatus are disclosed by which transmembrane movement of a preselected ion is magnetically regulated using a time-varying magnetic field. The fluctuating magnetic field is tuned to the cyclotron resonance energy absorption frequency of the preselected ion. This important discovery brought to light the interplay of local geomagnetic fields and frequency dependence in ion transport mechanisms. It has now been discovered that by utilizing and extending the principles of cyclotron resonance tuning, an unexpected and remarkable advance in the control and modification of developmental processes in living tissue can be achieved.
Currently, research efforts in the area of electronic medical devices which affect growth mechanisrns in living systems have focused on strain-related bioelectrical phenomena that have been observed in tissue such as bone, tendon and cartilage. During the last few decades, others have noted that electrical potentials are produced in bone in response to mechanical stress. It has been postulated that these electrical potentials mediate the stress-induced structural changes in bone architecture which were observed almost a century ago by J. Wolfe. Hence, although bioelectrical potentials are not well understood, numerous attempts have been made to induce tissue growth with electrical potentials and currents.
Much of this work has dealt with the repair of bone non-unions, i.e. bone fractures which have not responded to traditional therapies.
Bone formation, as will be known by those skllled in the art, is a complex biological process. It invoh~es the interaction of several characteristic cell .) ~h 2716.004 ~22~27 ~ypes, including monocytes, osteoblasts, ostcoclasts, osteocytes, chondrocytes, fibroblasts and undifferentiated bone mesenchymal cells which form a hard intercellular matrix of collagen and mineral crystals in which bone eells are embedded. The matrix is s~nthesized by osteoblasts which extrude collagen and mucopolysaceharide. By a proeess whieh is not fully understood, erystal nuelei form in the matrix to promote rapid alineralization by inorganic salts. Bone formation proceeds outward from ossifieation sites defined by clusters of osteoblasts. Osteoclasts then resorb bone dusing remodeling, whereby the bonc architecture is restructured to provide maximum strength.

A number Or bone disorders are known in whieh the integrity of the bone structure is compromised. Bone fractures produeed by aecidental trauma are quite common. The treatment of bone frsetures may be eomplieated by delayed union of the fractured ends, by bone non-union, or by abnormal unions such as pseudarthroscs.Moreover, in eerta;n bone diseases, e~teess bone tissue is formed (osteophytes;
osteoselerosis) which interferes with normal funetion. Alternatively, a shortage of bone tissue (osteopenia) may oeeur whieh deereases the fraeture resistanee of bone. Awidespread, generalized form of osteopenia known as osteoporosis is eharacterized by a reduetion in bone density àeeompanied by inereased porosity and brittlcness.
Osteoporosis is associated with a loss of ealcium from bone and is a major coneern oî the elderly, a group in whieh the disease is most prevalent. Osteoporosis signifieantly incrcases susceptibility to bone fracturcs and is generally eonsidered to be the most eommon bone disease in humans. Other maladies sueh as osteomalaeia, Paget's disease, osteomyelitis and osteoarthritis are also well doeumented in medieal literature.

A number of deviees and teehniques have been used by others with varying degrees of suecess to treat bone disorders. These inelude traetion, splints, easts and internal fixation by pins and plates to repair bone fractures. Abnormal bonegrowth has been successfully interrupted by the fusion of epiphysis to the bone shaft in a process referred to as "epiphysiodesis.~ ~one grafts have also been attempted with limited sueeess. In some instanees, where other treatment modalities fail, amputation of the affected limb is performed as a last resort.

1322~27 27 ~ 6.004 More recently, methods have bcen c~plorcd by others for altcring the electrical environment of bone tissue in an attcmpt to stimulate bonc growth in fracture repair. These efforts originally concentratcd on thc use of electrode implants by which direct current was flowed across or into a bone non-union or abnormal union to stimulate repair. Due to numerous drawbacks, including the associated risks of surgery required to implant thc electrodcs, altcrnate, non-invasive tcchniques werc pursucd.
While capacitively-8enerated electrostatic fields provided some beneficial results, the relatively large fields necessary were generally prohibitive. Finally, alternating, high-intensity electromagnetic fields were utilized to induce a voltage in bone. It was believed that by using the affected bone as a conductor, current flow through thc bonc could be induccd which would produce therapeutic benefits.

These prior art inductive dcvices are typified by the apparatus disclosed in U.S. Patent Number 3,893,462 to k~i~ entitled, ~Bioclcctrochemical Regcncrator and Stimulator Devices and Methods for Applying Electrical Energy to Cclls and/or Tissue in 8 Living Body~ and thc devices set forth in U.S. Patent Number 4~105,017 to RvabY et al. cntitled, "Modification of the Gsowth Repair and Maintenance Behavior of Living Tissue and Cells by a Specific and Selective Chan~e in Elec~rical Environmcnt.~ These investigators have rocused on the use of large fields to produce high induccd GUrrents in living ~issue with wcll-defined ~therapeutic" waveforms. The inventors of the present invention have approached the problem of regulating tissue growth from a different perspective. In its preferred embodiment, the present invention utilizes the interaction of fluctuating magnetic fields and preselected ions pre~cnt in biological fluids to influence developmental processes. Although a possible role of ~nagnetjc fields beyond the galvanic action of induced currents is briefly mentioned in U,S. Patcnt No. 3,890,953 to ~aus et a~., to Applicants' knowledge no investigator has prcviously controlled bone growth in the manner set forth in the present invention.

2716.004 132~

~rMARY OF THE I~VENTIOl~l In one aspect, the present invention provides an apparatus for coDtrolling the growth of living tissue. The novcl apparatus includes rnagnetic field generating means such as a ficld coil for generating a controlled, fluctuating magnetic field which penetrates a tissue in vivo, and an associated magnetic field sensing devicc for mcasuring the intensity of the magnctic field prescnt in thc tissue. In one embodiment, the magnetic field gencratin~ means and magnetic ficld sensor are enclosed within a housing along with a power sourcc such as a battery or thc like. In operation, the ma~netic field gcnerating means is positioned adjacent to a region of living tissue in a subject, the ~,rowth characteristics of which arc to be controllcd. A fluctuating, directional magnetic field is then gcneratcd by the magnetic ficld 8eneratin8 means.
The applicd magnetic flux density is directed along a predetermined a~is which passes through the tissue to be affected. In onc cmbodimcnt, the applied magnetic flux density along the a~is is superimposed on that component of the local or ambient magnetic field which is parallel to the predetermined a~is to create a fluctuating composite ficld. The resultant combined magnetic flux density which is parallel to the predctermined axis and which passes through the tissuc to be affccted is measured by the magnetic field sensor. The ma~netic field sensor dctermines thc nct avera~e valuc of the magnetic flus density which passcs through the tar~eted tissuc along the predetcrmincd a~is. In onc cmbodiment, the frequency of thc fluctuating magnetic field is set at a predctermined v~lue and the ne~ average value of the magnetic flux density is then regulated by adjustin8 the magnitude of the ~Ipplied magnetic field to produce a combined magnetic field havin~ a preselccted ratio of frequency-to-ficld magnitude which affccts the growth character;stics of the tar8et tissuc. In a prcfcrrcd embodiment, changes in the magnitude of the local magnetic field along the predetermined axis which would otherwisc altcr the magnetic flu~ density of the combined magnetic field parallel to thc predetermined a~is and which would thus produce a deviation from the desired ratio are counterbalanced by adjustment of the magnitudc of thc applied, fluctuating magnetic field. This adjustsnent is preferably made by microproccssing mcans in association with both the magnetic field gencrating -S-2716004 ~322027 mcans and the magnetic field sensor. Preferred ratios of frequency-to-field ma8nitude are determined with refcrence to the equation:

fc/B . q/(27rm) where fc is the frequency of the combined magnetic field in Hertz, B is the non-zero averagc valuc of the magnetic flu~ dcDsity of the combined magnctic ficld parallcl to the axis in Tesla, q/m is in Coulombs pcr kilogram and has a value of from about 5 ~c 105 to about 100 ~c 106. B prefcrably has a value not in c~cess of about 5 x 10 4 Tesla. In one embodiment, the values of q and m are sclccted with reference to the charge and mass of a preselected ion.

In another cmbodiment, chan8cs in the ambient magnetic field which would otherwise alter the ratio of frcqucncy-to-magnetic field are counterbalanced by adjusting the frequency of the applied magnetic field to maintain the preferred ratio.
The present invention also contemplatcs thc adjustment of both frequency and field magnitude to maintain the predctcrmined prefcrrcd ratio. Prcferably, the peak-to-pcak amplitudc of thc AC componcnt is in thc ran8e of about 2.0 ~ 10 5 to about 6.0 x 10 5 Tesla. Thc waveform is preferably substantially sinusoidal, but other waveforms are suitablc.

Thc present invcntion also provides a mcthod of controlling the growth charactcristics of living tissuc which includes in one aspect the steps of generating a fluctuating, diroctionally-orientcd ma~nctic ficld; positioning a rcgion of living tissue of subjcct, within thc rluctuatiDg, magnctic ficld so that thc ficld passes through thc target tissue parallel to a predctcrmined a~is that e~tcnds through thc tissuc;
mcasuring thc net average v~lue of the combincd magnctic flu~ dcnsity parallcl to the predetermined axis through the tissue, where the combined magnctic field is thc sum of the local magnetic field alon6 the predetermined axis and thc applicd magnetic ficld;
adjusting the frequency and/or magnitudc of thc applicd magnetic field to produce a combined ma~netic ficld along the a~is having a predctermincd ratio of frequcncy-to-magnitudc, where the predetcrmincd ratio influenccs thc growth characteristics of the ~322~27 271~ 004 target tissue; maintaining the prcdetermined ratio of frequency to magnitude of the combined field; and e~posing the target tissue to the combined magnetic field for a pcriod of time sufficient to affect the growth characteristics of the tissue. Other relationships between frequency and magnitude may be useful or even desirable in a particular application.

The present invention is particularly suitable for enhancing the growth of bone and cartilage to repair recalcitrant fractures and dama8ed cartilage surfaces. These and other advantages of the present invention will become more apparent from the following description of preferred embodimeDts and with reference to the drawings in which:

BBIEF ~ESCRI~IIOt~l OF THE DRAWINGS

Fi~ure I is a front elevational view of the present invention as applied to the treatment Or a fractured femur.

Fi~ure 2 is a front elevational view of the present invention with two treatment heads having field eoils and magnetic field sensing means shown in phantom.

Figure 3 is a front elevational view of one treatment head of the present invention with the housing broken away to illustrate the magnetic field sensiDg means.
:
Figure 4 illustrates the combined magnetie flu~t Or the present invention with ehanges in intensity ovor time.

Pigure S illustrates the fluctuating, Don zero average value of the eombined magnotic flux density.

2716.004 ~3~20`~7 Figure 6 is a block diagram of an embodiment of the present invention in which the circuit of the inventive apparatus i5 arbitrarily divided into convenient fu~lctional sections.

DE~TAILED DESCRIPTIQN OF THl~ PREFERIU~D EMBODI~ENTS

Referring now to Figure 1 of the drawings, tissue growth regulator 20 is shown in position on leg 22 of a subject. It is to be understood that both thc apparatus and the method of the present invention are suitable for use in eontrollin8 tissue growsh in an animal subject or a human subjeet. Thus, the target tissue which is ~o be controllcd, is a re~ion of living tissue in a subject, in other words, an "in vivo" target tissue. As used herein, the term "living tissue~ shall be defined, without limiting its customary meaning, as tissue which is capable of conducting metabolic functions such as cellular respiration a~d which possesses viable growth charaeteristics. "Growth characteristics" shall be dcfined, without limiting its customary meaning, as those attributes of living tissue which serve to mediate replication, growth, maintenance and repair. Although the stimulation of tissue growth will be emphasized in this description of preferred embodiments of the present invention, it is to be understood that the present invention can also be used to retard or impete the development of living tissue and may be suitable for other applications, including the prevention of abnormal tissue development.

Fraetured femur 24 is shown ha~ing fracture surfaces or ends 26 and 28 which are to be stimulated by the present invention to enhance tbe rate at which the bone fracture heals; As previously mentioned, the natural de~elopmental proeesses by whieh ends 26 and 28 reunite may be interrupted by a factor of known or unknown etiology resulting in a delayed union, abnormal union, or bone non-union. The present invention is particularly sui~able for use in the treatment of bone non-unions. In this embodiment, tissue growth stimulator 20 ineludes two treatment heads 30 and 32 which are positioned on Ieg 22 in the region of ends 26 and 28 in the opposed fashion illustrated in Figure 1. As will be explained more fully, it is important that treatment heads 30 and 32 be placed adjaeent the target tissue sueh that the tissue is within the ran8e of the 8~

.

~322~:~`7 7 ] 6.004 magnetic flu~ gencrated by the trcatment hcads. Also, althou~h it is prefcrred that two treatment hcads be employed in an opposed fashion as illustrated in Figure 1, a single treatment head or a plurality of treatmcnt heads 8reater than two may be suitable in some applications.

Referring now to Figure 2 of the drawings, retaining straps 34 and 36 are seen by which tissue growth regulator 20 is prefcrably secured into position on le8 22.
Othcr securing means may be suitable or desirablc in a particular application. It may also be desirable to provide tissue growth regulator 20 as a stationary unit or the like as an alternative to thc mobile unit depicted in Figures 1-3. Straps or belts 34 and 36 are attached to treatment heads 30, 32 by any convenient means, preferably in a manner which allows the distance bctwecn trcatmeot heads 30, 32 to be adjusled to be obtain the substantially opposed orientation shown in Figure 1. Hence, it is preferrcd that straps 30, 32 permit adjustment sufficient for tissue growth regulator 20 to be used on limbs of various sizes. Trcatment hcads 30 and 32 should be snugly but comfortably in position to prevent substantial movement relative to the tar8et tissue, illustrated here as fracture ends 26 and ~8. It is anticipsted that the present invention will be useful in conjunction wjth conventional plaster or plastic casts wherein tissue growth regulator 20 may be intcgrated directly into Shc cast architecture or may be mounted on the e1~tcnsion of the cast.

Referr;n8 now to Figures 2 and 3, each treatment head 30, 32 includes a housing 38, 40 of a non-ma~netic material such as plastic which encloses a ficld coil 42, 44. In addition, it is preferred that at least one treatment head cnclosc a magnetic ficld sensing device 46, such as a Hall-effect device, shown enclosed within housing 40 Or treatment head 30. Power source 48 is provided, preferably enclosed within one of ~he treatment hcads. Power sourcc 48 may comprise a dry cell battery or the likc. It is prefcrred that two or more separatc power sources be provided to minimize the number of circuit elements required. Housing 38 is also preferably provided with means by which battery 48 can be accessed such as a sliding panel or the like (not shown) to facilitate installation. It may also be suitable to mount battery 48 on the outside of housing 38 or to provite some other e~ternal arrangement. While it is a significant 7 1 6.004 fcature and advantage of ~hc present invention to provide a tissue growth regulator which includes a self-contained power sourcc, and thus which is both lightwcight and m,obile, othcr power sources such as an ac line source may be used in conncction with an ac/dc converter where mobility is not required.

Field coils 44 and 42 are the preferred means by which an applied magnetic field is Benerated in the present inveDtion. The radius of each field coil 44 and 42, as well as the turns of winding, may vary in accordancc with ~he principles of the present invention. Those skilled in the art will appreciate that other electromagnets or possibly permancnt magnets may be adapted for use in thc present invention and any such use is intended to comc within the scopc of the present invention. Field coils 44 and 42 arc most prefcrred since they provide a simple mcans for concentrating magnetic lines of force. Also, the present invention includes several components within a sin81e housing, and thcrefore shielding may be employed to prevcnt undesired interactions bctween componcnts.

In the most preferred arrangemcnt, thc geometry and relativc position of fielt coils 44, 42 during trcatmcnt are such that ficld coils 44, 42 operatc as Helmholtz coils. Those skilled in thc art will thus appreciate that in the most preferred atrangement, field coils 44, 42 are substantially idcntical, field-aiding, parallel coaxial coils separatcd by a distance cqual to thc radius of cach coil. In this most prcferred embodiment, the Helmholtz configuration produces an applied magnetic field in a prcdetersnined space between the coils. Referring to Fi8ure 4, this predctermined space 68 is occupied by the tar8et tissue, the growth characteristics of which are regulated by thc prescnt invention. This conccpt will bc more fully explained hercin. Hence, predetermined space 68 is shown through which magnetic field lines S2 extend parallel to pretetcrmined axis 50. Hcnce, magnctic field lines S2 pass through the target tissue, which i~ illustratcd here as fracture ends 26, 28.

It will bc appreciatcd that the target tissue will be subject to local magne~ic influcnces. As uscd herein, ~local magnctic ficld" shall be dcfined as the magnetic influences, includin~ the earth's magnetic field or ~eomagnetic field, which 2716.004 1322~27 create a local magnetic flu~ that flows through thc targct tissuc. "Ma~netic flux density~ shall be defined in the eustomary manner as the number of rnagnetic field lines pcr unit area of a section perpendicular to the direction of flux. Factors contributing to thc local magnetic field in addition to thc geomagnetie field may inelude localized regions of ferromagnetie materials or thc like. In one cmbodiment of the presentiDventiOD, ficld coils 42 and 44 are used to create an applicd, fluctuatiDg magnetic field which when combined with the local magnetic field parallcl to predetermined a~cis 50 produces a resultant or eombined magnetic field having a precisely controlled, predetermined ratio of magnetic flux density to frequency.

Refcrring now to Figure 3 of the drawings, magnetic field sensing deviee or magnetometcr 46 is shown iD housin~ 40 with the appropriatc leads 54, 56, 58 and 60, by which the field-sensing device is electrically connected to power source 48 and in one embodiment to mieroprocessing means 62. As will be appreeiated by those skilled in the art, the Helmholtz configuration of field eoils 42, 44 provides asubstantially uniform or equal applied magnetie ficld in activc volume or predetermined space 68 between the coils. Hcnce, tissue growth regulator 20 allows a substan~ially uniform appliet magnct;c field to be applied to the target tissue in predetermincd space 68. The direction of thc applied ma~netic flux defines the direction of predetermined a~is S0. That is, the flux of the applied magnetic field is always in the same direction as prcdctcrmined axis S0. ID thc preferred embodiment of the invcntion, this applied magnetic flux is superimposcd on thc local ma8nctic flux in predetermincd space 68 Thc field lines of this local flux componcnt are shown by rcferencc numcral S3.

Magnetometer 46 is positioncd in growth rcgulator 20 to measure the total or eomposite magnctic flux which passcs through prcdetermincd space 68 parallel to prcdetermined axis 50. It will be understood, thcn, that ma~nctometer 46 is provided to measure the composite magne~ie fic1d along a~is 50. The local field component cither augments or decrcascs thc applicd magnctic flux unlcss thc local ficld component is zero.
This is an important fcature of the prcsent invention. Thc relatiYely low applied flux densities and precise predetermined relationships of combined flux density and frequency provided by the present invcntion must bc maintained during treatment, 27160~4 ~22~27 notwithstanding the influence of the local magnetic field. This is achieved in essentially two preferred manners which will be explained more fully herein. Thus, magnetometer 46 is provided to determine the magnitude of the magnetic flux density of the local magnetic field. Hence, in one embodiment of the invention, prcdetermined space 68 is occupied by a region of living tissue of a human or animal subject.
Predetermined a~cis ~0 which projects through predetermined space 68 and thus through the tar8et tissue is dcfined by the relative position of tissue growth regulator 20 with respect to the tar8et tissue. Predetermined axis 50 is in the same direction as the applied magnetic flux generated by field coils 42, 44 through predetermined space 68.
During this proccdure, magnetometer 46 measures the total magnetic flux density parallel to predetermined axis 50 which passes through tho target tissue. This total or composite rnagnetic flux density is the sum of the applied compoDent and the local component. The local component may at times be in thc same direction as the applied flux and at other times be in directions other than the applied flux. At times the local component may also be zero. These changes in the local component along the axis are produced by changes in the direction of predetermined axis 50 as tissue growth regulator 20 is rcpositioned such as when an ambulatory patient receiving treatment moves le8 22.
Thus at Tl the aPPlied flux generated by field coils 42, 44 may be parallel to a north-south axis, pcrhaps when the patient faces west. Since the directioa of predetermined axis 50 is defined by the direction of the applied flux, in this position, prcdctermined axis 50 is shereforc also in the north-south direction. At T2, the patient may turn to the north causing a 90 de8ree rotation of field coils 42, 44 such thst the applied magnetic flux is now parallel to an east-west axis. Accordingly, predetermined a~is 50 is then also in the east-west direction. In most cases, the local component will be different in different directions; hence the compositc flux measured by magnetometer 46 alongpredetermined axis 50 will chan~c in response to changcs in the position of tissue growth regulator 20 with respect to the local magnetic field. The net average value of magnetic flux density is accordingly regulatcd to adjust to the change in composite flu~.Therefore, growth regulator 20 is preferably a mobile unit which is a significant advantage.

27 1 6.004 The unexPected and superior results of the present invention are achieved by creating a fluctuating combined or composite magnetic field having a magnetic flux density parallel to predetermined axis S0, where the combined magnetic flu~ density along axis S0 is maintaincd at a predetermined relationship to the frequency of the fluctuations. In this embodiment, the combined ma~netic flu~c density parallel to predetermined axis 50 has a non-zero net average value. ~s illustrated in Figure 5 of the drawings, the therapcutic magnetic field of the prcsent invention can be thought of as a static field having reference level A on which a fluctuating magnetic field is superimposed. It comprises an ac component which varies in amplitude but not direction and a dc reference around which the ac component varies. Reference level A
is the non-zero avcrage value of the flu% density (B). Therefore, it will be understood that the non-zero avera~e or net average value of the composite magnetic flux density along predetermined axis 50 is utilized since the magnitude B of the composite flux density changcs at a predetermined ratc due to oscillation or fluctuation of the applied magnetic flux. Thus, an avera8e value is utilized which is a non-zero average value illustrated at point (c). This reflects that although the composite magnetic flux density along the a%is is oscillating at a controlled rate, ~he composjte field is regulated by the intensity of the applied field to cnsure that the composite field is always unipolar; that is, the composite field is always in the same direction along predetermined axis 50.

As stated, it has been found that rather precise relationships of the flux density of the combined magnetic field to the frequency of the fluctuations are used in the present invention to provide therapeutic results~ These ratios of frequency to composite flux density are found in accordance with the following equation:

fc/B q/(2 1I m) where fc iS the frequency of the combined magnetic field in Hertz, B is the net average valuc of the magnctic flu~ dcnsity of the combined magnetic field parallel to predetermined axis S0 in Tesla, q/m has a value of from about S x 105 to about 100 x lo6 Coulombs per kilo~ram. B preferably has a value not in excess of about 5 x 10 4 ~3~2~q~7 2~ 1 6.004 Tesla. To stimulate bone growth, as an e~ample, the following frequency and associated combined magnetic flu~ density (B) is preferred:

fc (Hert~ B (Tesla) 16.0 2.09 ~ 10 5 To retard bone growth, the following frequcncy and associated combined magnetic flux density (B) is preferred:

fc (Hertz) B (T~
16.0 409~t 105 Whilc the e~act mechanism by which growth characteristics of the target tissue are affected by the present invention is not fully understood, as will be explained morc fully in connection with the method of the present invention, rernarkable results are achieved by tuning tho combined field to resonant absorption frequencies of preselected ions.

Thereforc, it will bc reatily understood by those skilled in the art that tissue ~rowth regulator 20 inclutes in ono aspect a magnetic field 8eneratiD8 mcans for pro~iding a~ oscillating magnetic field parallel to a predetermined a~is. Magnetic growth regulator 20 also preferably includes magnctic ficld sensing means by which the magnetic flux density patallol to the predctermined a~is is measured. A
microcontrolling mcao~ is also preferably provided in tissue growth regulator 20 by which a predctermined relationship bctween the magnetic flu~ densi~y parallel to the prcdc~ertnincd a~tis and the frequency of the magnetic field oscillation is created and maintained as tissue growth rcgulator 20 changes orientation w~th respcct to the local magDetic field. Tissue ~rowth regulator 20 is thus used to create, monitor and adjust a magnetic field of predetermined paramctcrs in predetermined volume 68. While this predetermined relationship is preferably maintained by adjusting the applied flu~ to compensate for changes in the local field component, alternatively the frequcncy can be adjusted to preserve the desircd ra~io.

2716.004 ~322027 In use, living tissue is placed within predetermined volume 68 and is then subjectcd to a rluctuasing magnetic field as described for a duty cycle and pcriod of time sufficient to propcrly influence the growth characteristics of the target tissue. In the most prererred embodiment, this influence will comprise the acceleration of ~rowth characteristics to cause the proliferation and growth of tissue cells, vvhereas in another embodiment this influence will act to retard growth and proliferatiom While the length of time necessary for successful treatment may vary, it is anticipated that up to about 100 days of treatment of a bone aon-union to stimulate bone growth will provide beneficial results. Longer treatment may be desirable in certain applications.

In another embodiment of the present invention, values for q and m are determined with reference to a preselected ionic specics. It will be known by those skilled in the art that the biochemical milieu of living tissue comprises a mi~ture of various ions in the intercellular and interstitial fluid. These ions include potassium ions, magnesium ions, sodiums ions, chloride ions, phosphate ions, sulfate ions, carbonate ions~ bicarbonate ions and the like and various ions formed by the dissoçiation of amino acids, proteins, sugars, nucleotides and enzymes. Applicants have found that by utilixing the values of eharge and mass for a preseleeted ion in the equation set forth above, which will be reeognized by those skilled in the art as the cyclotron resonance relationship solved for fc/B, ratios of frequency to magnetic flu~c density can be determined whieh serve to regulate growth charaeteristics of living tissue in accordance with the present invention. Evidence to date indicates that by us;ng the charge-to- mass ratio of a preselected ion, a specific cyclotron resonance frequency for the ion can be determined. By then tuning tissue growth regulator 20 to maintain a combined magnetic flux density having the proper cyclotron resonance frequency, living tissue containing the preselected ion can be treated to bring about changes in growth characteristics. Again, evidenee indicates that tho beneficial results of the present invention in this embodiment are achieved when the preselected ion absorbs energy from the magnetic field of the present invention having the desired parameters. It is believed that this increase in energy promotes the transmembrane movement of the preselected ion across the cell membrane Or one or more cell types comprising the target 2716.004 1322027 tissue. By enhancing the transmembrane movement of pteselccted ions in this manner, cell growth and tissue development caD be increased or decreased by the present inventiom For iDcrcasing the growth of bone tissue, it is preferred that the prçselected ion comprise Ca~ or M8++. To retard or inhibit bone growth, it is preferred that thç
prcselected ;OD comprise K~.

It will be appreciated by the prior e~planation of preferred embodiments of the present invention and from the equation for establishing a cyclotron resonance relationship, that either the frequency of thc fluctuating magnetic field or the magnitude or intensity of the magnctic flux density along thc predetermincd axis, or both the frequency a~d the intensity of the flu~ density, caD be adjusted to provide a magnctic ficld within volume 68 which has the desired characteristics. Howcvcr, as stated, it is preferred to maintain a constant frequency which thus requircs that the intensity of the applied magnetic flux density bc adjusted to compcDsate for chan~es in the local magDetic field in order to maintain a constant ratio of frequcncy to magnetic flu~ density. For c~cample, if it nccessary to maintain a frequency of 15 Hz and an average flux density of 1.95 ~ 10 5 Tesla to affect growth charactcristics of thc targct tissue, changes in the local field which would otherwise cause unwanted deviations in the combined magnetic flux density must be corrected by incrcasing or decrcasiDg the ap~lied magnetic flux derlsity accordin81y. This is most preferably performcd by the microcootrollcr in connection with bo~h thc field generatiDg means and the ficld-sensing device. Alternatively, as stated, if chsnges in thc combincd magnctic flux density along the a~is will occur due to changes in the orientation of tissue growth stimulator 20 with respect to the local ma8netic field, the frequency of the oscillations can then be changed so that the preferred therapeutic ratio is maintained. Once a~ain, it isimportant to realize that the value of ~ is the avera3e composite magnctic flux dcnsity parallel to the predctcrmined a~is since the magnitude of the flu~ density changes as the field is oscillated. It will be understood that detection of changes in the magnetic field due to chan~es in the ambient component should be at intervals frcquent enough to provide a frequcncy-to-magnetic ficld ratio which is substantially constant, notwithstanding the changes in the local field component.

'7 )04 _ 1322027 RcfcrrinR now to Figure 2 of the drawin~s, cach field co;l ~2, 44 prcfcrably has up to about 3000 turns or loops of conducting wire, ~hc diamcter 1;) of each loop bci~g prcfcrably up to about 300 centimcters. Thc Dumber of turns of wire D, thc diametcr of thc coils, thc separation of the coils, and thc wirc 8aU8c arc critical only insofar as convc~tional practicc requircs constraints on thcsc tnd othcr desigD
parameters to allow optimal performance characteristics in ~chievin~ predetermincd flux densitics as requircd in the prefcrrcd practicç of thc prescnt invcntion. As stated, othcr magnctic ficld generat;n3 means may bc suitablc for usc in thc prcscnt invention and are contcmplatcd as falling within the 5COpC of this invcntion~

It i5 also to bc undcrstood that thc applicd magnctic ficld which rcsults in a combincd magnctic flux density along predetermincd axis 50 may bc produccd by a sinusoidal signal or from a full-wavc rcct;ficd signal applicd to ficld coils 42, 44. It may also bc appropriatc in some instances to rcduce components of the local magnctic field which arc not parallcl to pretetcrmincd a~is S0 to zcro through the use Or add;tionsl coils positioned at ri8ht anglcs to trcatmcnt hcads 30, 32 to creatc an opposite but equal ficld, but this is not dccmcd ncccssary. It may also be suitable to rcduce thc local magnctic ficld çomponcn~ to zcro throughout trcatmcnt using add;tional coils or thc like.

Rcfcrri~ now to Figure 6 of thc drawin8s, a block diagram is shown which depicts onc prefcrred arrarigemcrlt of thc circults of ti~suc growth rcgulator 2~ in functional scgments. Nlumcrous othcr circuit arrangcmcnts may be possible if theprinciplcs of thc prcscnt invcntion arc faithfully obscrved. Microcontrollcr or microprocessor 100 i5 sccn by which thc composite magnetic flcld ;s maintaincd at a coDstaDt prcdctermiDct lcvcl tcspitc chaD~cs ln thc ambicnt component as previously dcscribcd. In this rcspect, iDpUt 10~ Is provided by which ~ sct point valuc of the predctcrmined compositc magnctic flu~ dcn3ity along a prcdctcrmined axis through the targct tissuc is iDpUt into microproccssor 100. ~5 will bc shown~ the compositc field strcn~th is comparcd to this sct point valuc to Rcncratc an crror cqual to thc diftercnce in thc sct point valuc and thc mcasurcd valuc of the composi~c magnctic tlux dcnsity alont thc a~is.

27 1 6.004 Magnetic ficld sensor 104 is provided by which the magnitude of the composite field which passes throu8h thc target tissuc along thc a~is is lacasured. It is preîerred that magnetic field scnsor 104 comprisc a Hall-effcct dcvicc which, as will bc known by thosc skilled in thc art, produccs an analog signal. Thc magnetic field scnsor 104 coDstantly monitors the compositc magnetic field, sending a signal to microproccssor 100. It will be uDderstood that the output of a Hall-cffect magnetic scnsor is rclatively small; thus, magnctic ficld scnsor amplifier 106 is providcd by which the signal from magnetic ficld sensor 104 is amplifiet, for example, up to three thousand times its original valuc. Sincc a Hall-cffcct device produces an analog signal, analo~-to-digital converter 107 is provided by which the amplified signal from magnetic fieJd sensor 104 is convcrtcd to a digital signal which can bc used by microproccssor 100. It is preferrcd that thc analo to-digital convcrter bc provided on-board thc microprocessor chip.

As will be apprcciated, the amplification of the magnetic field sensor signal may produce an unwantcd noise level. Also, suddcn changes in thc magnctic ficld intensity may occur which make it difficult to dctcrmine the truc averagc value of the compositc magnctic flux dcnsity. Hence, the signal from analo~-to-digital convcrtor 106 which is input into microproccssor 100 is filtcred by softwarc filtcr 108 to rcmove shot noi~c and sudden fluctuations in thc composite ficld tctectcd by magnetic field sen~or 104. Although it is prcfcrred that filter 108 comprise software in microproccssor 100, a discretc filter could bc uscd. In this cmbodimcnt, software filter 108 is a digital filter, prcferably an integrator with a timc constant of appro~imately 0.5 seconds. In othcr words, the changcs in thc magnitudc of thc compositc magnctic ficld which are compcnsated fOF by incrcasing or dccreasin~ the applied field are long-term changes of 0.5 seconds or more which result primarily ftom changes in the orientation of magnetic growth regulator 20 with respect to the ambient field componcnt. Hence, the time conssant of filter 108 should bc such that momentary fluctuations are filtcrcd out.

Microproccssor 100 includes logic which calculatcs the non-zero net averagc value of the compositc magnetic flux dcnsity. This non-zcro avcragc value is then comparcd at comparator 110 in microprocessor 100 to the predetermincd dc 7 1 6.004reference or offset value which is input into microprocessor 100 via input 102. lt should be noted that this reference value is preferably established by dedicated circuitry in microproccssor 100, although variable input mcans could be included by which thc sct point value could be changed. An error statement is then 8enerated defining the difference in the measured ~alue of the composite magnetic flu~ density and tbe set point or reference value. Microprocessor 100 then tetermines the ~nagnitude of the output necessary to drive magnetic field generating coils 112 to bring the composite magnetic flux density back to the set point.

Software field modulator or oscillator 114 is provided by which an ac or fluctuating cornponent is superimposed on the digital output signal which is input into digital~to-analog converter 116. From the previous discussion of the present invention, it will be understood that software field modulator 114 of micraprocessor 100 in the preferred embodiment of the present invention is preset to a fixed, predctcrmined frequency to produce the desired predetermincd, growth-regulating ratio of frequency-to-magnetic flu~ density value. In another embodiment, the feedback system of the present inveDtion is such that changes in the composite magnetic flu~ density arc mcasured, whereupon microprocessor 100 determines the necessary change in frequency to maintain the predetermined relationship. In that embodiment, software field rnodulator 114 produces the requisite ac frequency. It is a8ain preferred that digital-to-analog converter 116 be provided on-board the microprocessor chip. Hence, software field modulator 114 proviJes the ac component at node 118.

The signal from digital-to-analog converter 116 is fed to voltage-to-current amplificr 120, the output of which drives magnetic field generating coils 112 in the desired manner. Hence, the composite field is held substantially constant despite changes in the ambien~ component.

While several arrangen~ents of power sources are suitable, it is preferred that power supply 122 be providod to power magnetic field sensor amplifier 106, microprocessor 100 and magnetic field sensor 104, the latter via bias circuitry 124.

A separate power source 126 is preferred for voltage to current amplifier 120.
.19.

27~6.004 _ 1~2~D~7 Having fully described the apparatus of the present invention, including its manner of construction, operation and use, the me~hod of the present invention will now be described. It is to be understood that this description of the method ineorporates the foregoing discussion of the novel apparatus. In this aspect, the present invention provides a method of regulating the growth characteristics of living tissue. This is achieved in one embodiment by generating a fluctuatin8, directionally-oriented magnetic field which projects through the tar~et tissue. A number of magnetic field ~enerating rneans sre suitable for this purpose, but the tissue growth stimulator previously described is preferred for use herein. The magneticfield so~,eDerated hasa magnetic flux density of precisely controlled parameters which passes through the tar8et tissue parallel to a predetermined axis projecting through the tissue. As will be known by those skilled in art and as has been clearly explained, the local magnetic field to whieh the tar8et tissue is subjected will have a eomponent which is parallel to the predetermined a~cis and which thus aids or opposes the applied or generated magnetic field along the axis. At times, the local componont may be zero. In the method of the present invention, the density of this combined magnetic flux, and more specifically the average non-zero value Or the combined magnetic flux density, is controlled to provide a preeise relationship between the flux density along the axis and the frequency of the applied magnetie field which is oscillatin8 at a predeterrnined value. Most preferably this is aeeomplished by adjusting the in~ensity of the applied field to eompensate for ehanges in the loeal field. Thus, in one embodiment, the present invention provides a method of regulatin~ growth characteristics Or living tissue by creating a magnetic field whieh penetrates the tissue and which has a predetermined relationship between frequeney of osc;llation ar~d average flux density. The predetermined relationship or ratio of frequeney-to-field magnitude is determined with referenee to the equation:

fc/B - q/(2~ m) where f~ is the frequency of the combined magnetic field along the predetermined axis in Hertz, B is non-zero net avera~e value of the magnetic flux density of the combined magnetic field parallel to the axis in Tesla, q/m ;s in Coulombs per kilogram and has a 1322~27 7 1 6.û04 value of from about S x IOS to about 100 x 106. B preferably has a value not in e~cess of about S ~ 10 4 Tesla.

In order to create this fluctuating magnctic field having the desired parameters, the composite magrJetic field parallcl to the predetermined a~is is constantly monitored. As stated, this is preferably carried out with a Hall effect device or the like which produces an analog signal. This analog sigDal is periodically sampled by microproccssing means which then calculates thc necessary frequency and/or magnitude of the applied magnctic field to maintain the preprogrammed, predetermined ratio prcviously describcd. Of coursc, it will now bc undcrstood that it is thc combincd magnctic flux which is scnscd by thc magnetic field sensor. The magnetic ficld gcncrating means is used to adjust the magnitude of this composite f;eld where appropriate.

In one embodiment, the method includes controllin8 the average valuc of the applicd magoetic flux dcnsity along a predctermincd a~is to maintain a prcdctcrmined ratio of frequency-to-composite magnctic flux dcnsity. In anothcr embodiment, thc frequency of the flwtuations is adjustcd to maintain this rclationship in which chan8cs in the combined magnetic flux density due to changes i~ the local magnetic field are deteeted. Moreover, a eombination of these two methods may be used vvSerein both the frequency ~Ind the magnitude of the magnetic field flu~ density are adjusted to maintain the predetermined relationship of the present invention.

Hence, the method of the present invention includes the steps of eroating and msintaining a predetermined relationship between the frequency of a fluctuatiDg magnetic field to the flu~ density of the field. In particularly preferrcd embodiments, the ratio of frequency-to-flws density is determined with reference to the vslues: a frequency of 16 Hertz and an average flux density of 2.09 ~ 10 5 Tesla. This combination of frequency and flux density is partieularly useful in stimulating bone growth.

-` 1322027 6.004 The following frequency and corresponding flux density is useful in retarding bone growth: 16 ~lertz and 1.27 x 10-5 Tesla.

In a preferred embodiment of the method of the present invention, the ratio of frequency-to~flux density is determined by selecting a preselected ion present in the interstitialo or intracellular fluids associated with the target tissue and tuning the fluctuating composite magnetic flux density to the specific cyclotron resonance frequency for the ion. The preferred ions for stimulating growth are ~a++ and Mg++. The preferred ion for inhibiting bone growth is K+. In addition to these ions, other ions which may be useful in the present inventlon are set forth in the following table for purposes of illustration: -Hydrogen, H+
Lithium, Li+
Sodium, Na+
Chlorine, Cl-Bicarbonate, HC0-3 Hence, in addition to the apparatus of the present invention, the pre6ent lnvention provides a method ,for controlling growth characteristics of living tissue which include~ the steps of creating a fluctuating magnetic field of predetermined frequency and flux density along an axi~ projecting through a predetermined ~olume and positioning a target tissue within this predetermined space such that it i8 exposed to the fluctuating magnetic field. The predetermined parameters of the fluctuating magnetic field are determined by measuring the net average value of the combined magnetlc flux density parallel to the predetermined axis through the tissue, where the com~ined magnetic field is the sum of the local magnetic field along the predetermined axis and the applied magnetic field. The frequency and/or magnitude of the applied magnetic flux den8ity is then ad~usted to produce a combined magnetic field along the axis having a predetermined ratio of frequency-to-flux density. Thi8 predetermined ratio influences the growth characteristic6 of the target tissue. The tissue is exposed to '' X

~322027 -- -2 7 ] ~.004 the fluctuating magnetic field for a duty cycle and a pcriod of time sufficient to propcrly affect the growth characteristics of the tissue.

The following examples are providcd to further describe and illustrate the present invention and are in no way intended to limit the scope of thc appended claims.

EXAMPI,E A

Twelve wcll plates were prepared by placing a sterilc SS screen and a raft formed of a section of sterile triangular lens paper into cach well. 0.5 ml of prepared BGJb medium to which antibiotics had Seen added was then introduced into each well which was sufficient to float cach raft. Petri dishes were then prepared by placing squarcs of either sterile unbleached muslin or gauze sponges into each dish.
The gauze sponges were moistened with a small amount of prepared Hank's Balanced Salt Solution (HBSS) medium. Ei8ht day old incubated chick eggs (whitc leghorn) were candled, from which 26 cmbryonated cggs were selected. Chick fcmurs were cxplanted to the gauze sponges and then moved to the muslin for cleaning. The identity of right and left fcmurs was maintained throu~hout thc procedure. The lcngth of each femur was then measured to the ncarest 0.1 millimeter and the measurement recorded. Sets of control platcs and sets of experimental plates were then designated. The left femurs were placcd in the wells of the control plates and right femurs were placed in the wells of the e~perimental plates. Two femurs were placed in each well and each well was numbered. Throughout the procedure, the medlum was replenished every other day.
Throughout the test, both control and e~perimental femurs were e~posed to the ambient magnetic field of the sest facility. In addition, an applied, directionally-oriented fluctuating magnetic ficld was 8enerated by a pair of Helmholtz coils to which the e~perimcntal femurs werc e~posed in the following manncr. The composite magnetic flu~ density along a predetormined a~is projecting through the femurs was measured with a magnetometer. One set of c~perimental plates wcre e~posed to a composite magnetic flu~t, that is, the combined ambient field and applied field along the axis, which fluctuated at a frcquency of 16 Hz and a peak-to-Peak amplitude of 3.0 x 10 5 .
27 1 6.004 Tesla. For this sct of experimental plates, the average magnetic flux density of thecomposite magnetic field parallel to the a~is was maintained at 2~09 ~ 10 5 Tesla. This corresponds to the frequency to magnitude ratio for Ca++ using the cyclotron resonance relationship of the preser t invention. A second sct Or e~perimental plates were e~posed to a combined or composite magnetic field in the same maoner where the frequency was set at 16 Hz, but the average flux density along thc a~is was maintained at 4.09 ~ 10 5 Tesla. This corresponds to the frequcncy to magnitude ratio for K+ using the cyclotron resonance relationship. A third set of e~perimental plates werc el~posed to a fluctuating composite magnctic field in this fashion where the frequcncy of the fluctuations was 16 Hz and the avcrage flux density was maintained at 1.27 x 10 5 Tesla which corresponds to the frequency to magnitude ratio for M8~ USiD~ the cyclotron resonance relationship.
The parameters of the fluctuating magnetic fields were maintained at thesc predetermined ratios for the duration of the trcatment, seven days. Again, the control platcs were exposed only to thc ambient field. Following treatment, the chick femurs were fixed with 0.7 ml of 109~ NBF. The length and mid-shaft diameter of each femur was measured and recorded. The ratio of length to mid-shaft diameter was determined for each femur.

In Table 111, the mean lengths and standard deviation before (ToL) and after (T~L) treatr~ent are set forth for the control and c~cperi;nental femurs in thc Ca e~pcriments. The value of the mean and standard deviation for Icngth/diameter is also set forth.

Control ExDerimen~al ToL T7L T~L/D ToL T~L T~L/D

4.~ 8.15 9.S3 4.7 9.4 ~.8 SD 0.3 0.5 1.3 0.3 0.75 ~ 1.0 The results indicate that ~hose chick femurs treated in accordance with the present invention were 159~ longer, 41% thicker and 22% more robust (length/diameter) than the control femurs.

27 1 6.004 In Tablc IV, the mean lengths and standard deviation before and after treatment are set forth for the control and experimental femurs in the K+ e~periments.
The value of the mean and standard deviation for length/diameter is also set forth.

TABLJ~ IV
CQn4QI E~?~Derim~al ToLT~L T7L/D ToL T7L T7L/D

4.7 8.1 9.9 4.7 7.6 10.3 SD 0.2 0.5 0.2 0.2 0.4 0.6 The results indicate that those chick femurs treated in accordance with the present invention were 7% shortcr, 9% thinncr and 4% more gracile (length/diameter) than the control femurs.

In Table V, thc mean len~ths and standard deviation before and after treatment are set forth for the control and experimcntal femurs in the M8++
e~periments. The value of the mean and standard deviation for length/diameter is also set forth.
TABLE V
ContrDI E~Deriment~l ToL T7L T7L/D ToL T7L T7L/D

x 4.7 7.6 9.9 4.7 ~.4 8.0 SD 0.3 O.S 0.7 0.3 0.8 0~8 The ro~ults indicate that those chick femurs troated in accordance with the present invention were lO.SYa Ionger, 37.59b thicker and 19.29b more robust (length/diameter) than thc control femurs.

pLE a }latches of twelve 3keletally mature white rabbits were divided randomly into groups of thrce each. Each rabbit was anaesthetized, then the lateral surface of each leB (knee to ankle) was shaved and preparcd for surgery. A 2.0 cm incision was made beginning at the knce and e~tending toward thc anklc along the 1322~27 716.004lateral surface of the leg. The fibula was exposed by division tloog the anterior/lateral compartment line. An incision was made in the periosteum of each fibula, and thcperiosteum was reflected dorsally and ventrally for a proximodistal distance of 1.5 cm, beginning 5 mm from the union of tibia and fibula. The periosteum of the right fibula was allowcd to return ~o place, and thc wound was closed in layers. The ri8h~ fibula thus served as a sham-operated control. Thc left fibula was treated similarly, e~cept that a I cm section of bone was c~cised, and the periosteum was prescrYed across thc gap.
The wounds werc likcwise closed in layers. Thc left legs thus served as operated test specimens. After surgery, the animals were given analgesics and returned to cages for recovery.

The first group of three animals were returned to their cages and given no further treatment. The first group servcd as controls. The second group were placed in cages of identical proportions, placed bctwcen pairs of Helmholtz coils. The composite magnetic flu~ density along a predetermined a%is corresponding to the axis of the pair of coils and projecting through the bodies of the animals, including the fibulae, was measured with a magnetometer. The coils wcre used to apply a directionally-oriented fluctuating magnetic field to thc entire body of each animal. Thus, each animal in this group was e~cposed to a compositc magnetic flux, that is, the combined ambient field plus an applied field along the a~is of the coils, which fluctuated at 35.6 Hz, with a peak-to-pcak amplitude of 3.0 % 10 5 Tcsla of the AC component with the static magnetic flu~ density parallel to ~hc cagc a%is at 4.65 ~ 10 5 Tcsla, and thcse conditions corresponded to thc frequency-to-magnitude ratio for Ca++ ions, using the cylotron resonance relationship of the present inventiom The above described ma8netic flux was applied for 24 hours per day for four weeks.

The third group of three animals were treated with an identical combined static and alternating magnetic flu%, e%cept that the duty cycle was reduced to 3 hours per day.

2716.004 1 3~ 27 The fourth group of animals wcre treated with a similar set of magnetic flu~es for 24 hours per day~ except that the frequency was adjusted to 60.5 Hz, which, given the static magnetic flux dcnsity parallel to thc cage a~is of 4.75 X 10 5 Tesla, corresponded to the frequcncy to magnitude ratio for Mg+ l ions, using thc cyclotron resonance relationship of the prcsent invention. Thc parameters for all fields were maintained for the duration of the e~periment, four weeks.

At the end of the experiment, the animals were sacrificcd, and the legs were removed by disarticulation at the knee and ankle. The legs were ~t-rayed in the frontal plane (A-P a~is). From these ~-rays, the width of the callus filling theosteotom!/ defect was measured at its narrowest point io the gap. The diamcter of the fabella, a small sesamoid bone near the knee was also measured from the ~-rays.
Subsequently, the muscular tissue was stripped from the tibia and fibula, and the bones were clamped in a fi~ation device. A stylus attached to a force transducer was then applied to the fibula, and it was anteriorly or posteriorly bent to the e~tent of I mm from its normal pro~imodistal a~is, at the distance of 2 cm from the attachment of the fibula to the tibia, i.e., 1.5 cm pro~timal to the distal end of the os~eotomy gap. The stiffness (force/mm displacement) of the opcrated side was then compared to that of the sham-operated sidc of the leg, and to the operated side of the control legs.

In Table VI, The mean callus widths and standard deviations for all groups are et forth, plus a statistical comparison of e~periments and controls. In Tablos Vl throu8h Vlll, t is student's t value.

TALLE Vl CalluS Widths ~Q~ Width Variation Ca+ 24 Hours 4.16 mm S.D. 0.61 Ca++ 3 Hours 3.72 mm S.D. O.S5 Mg++ 24 Hours 4.24 mm S.D 0.78 Control 2.S7 mm S.D. 0.36 Ca/24 vs. Control S - 3.55, p < .05 Ca/03 vs. Control - t - 5.05, p ~ .05 Mg/24 vs. Control - t - 3.07, p ~ .05 2716.004 ' 1322027 In Table VII, the diameters of the fabcllae are comPared by groups, and are ses forth in thc same manncr as for Table Vl.
T~VII
Gr~UD Diametcr Variation Ca++ 24 Hours 3.18 mm S.D. 0.12 Ca~+ 3 Hours 3.17 mm S.D. 0.34 M8 24 Hours 3.76 mm S.D. 0.25 Control 2.22 mm D.S. 0.38 Ca/24 vs. Control, t . 3.41, p < .05 Ca/03 vs. Control, t - 2.63, p ~ .06 M8/24 vs, Con~rol, t ~ S.3S, p ~ .OS

In Tablc Vlll, the relative stiffnesses Or the experimental and control operated sidcs to their oppositc sham-opcratcd sidcs sre comparcd and sct forth.Comparisons between control and e~perimcntal valucs are also set forth.
T~LE Vlll tivc Stiffness GrouD ~Q Variation Ca++ 24 Hours .631 S.D. 0.383 Ca ~.+ 3 Hours .233 S.D. 0.004 M8 24 Hours .594 S.D. 0.571 Control .194 D.S. 0.170 Ca/24 vs. Control . ~3209~
Ca/03 vs. Control . ~120%
M8/24 vs. Control, ~2SS9~

From thcsc data, it is evidcnt that an spplication of thc mcthod of thc present invention matcrially stimulates the growth and regéneration of bone in wholc animals, as compared to animals not stimulatod accordin8 to the mcthod of thc prcsent invention. The amount of callus in thc region of 8 dcfcct ;s incrcased, the stiffncss of thc repair, and hence its weight-bearing ability, is increased. The growth of the bones is enhanced generally, as evidenced by thc diametcrs of the fabellae, bones not subjected to any surgical treatment.

While particular embodiments of this invention sre shown and described herein, it wil} be undcrstood, of course, that thc invontion is not to be limited thercto, sincc many modifications may bc madc, particularly by thosc skilled in thc art, 27 1 6.004 in light of this disclosure. It is contemplated, thereforc, by the appended claims, to cover any such modifications as fall within the true spirit and scope of this invention.

~;

:~:

.

-29~

Claims

1. An apparatus for regulating in vivo tissue development comprising:
means for generating an applied magnetic flux parallel to a predetermined axis and projecting through a predetermined space containing in vivo said tissue;
means for measuring magnetic flux density parallel to said predetermined axis in said predetermined space;
means associated with said flux generating means for fluctuating said applied magnetic flux; and means for creating and maintaining a relationship between the rate of fluctuation of said magnetic flux and the intensity of said magnetic flux density, where said predetermined relationship regulates the development of said tissue, and where said magnetic flux density has a non zero net average value.

2. The apparatus for regulating in vivo tissue development recited in claim 1, wherein said means for generating an applied magnetic flux includes at least one field coil.

3. The apparatus for regulating in vivo tissue development recited in claim 1, wherein said means for generating an applied magnetic flux includes two field coils arranged in a Helmholtz configuration.

4. The apparatus for regulating in vivo tissue development recited in claim 1, wherein said means for measuring the magnetic flux density parallel to said predetermined axis in said predetermined volume includes a magnetometer.

5. The apparatus for regulating in vivo tissue development recited in claim 1, wherein said means for creating and maintaining said relationship includes microprocessing means.

2716.004

6. The apparatus recited in claim 3, further including a first housing of a non-magnetic material enclosing one of said field coils and a second housing of non-magnetic material enclosing the other of said field coils.

7. The apparatus for regulating in vivo tissue development recited in claim 6, further including means for securing said apparatus into position relative to said tissue.

8. The apparatus for regulating in vivo tissue development recited in claim 7, wherein said securing means includes two adjustable straps attached to said first and second housings.

9. The apparatus for regulating in vivo tissue development recited in claim 1, wherein said means for fluctuating said applied magnetic flux includes an oscillator.

10. The apparatus for regulating in vivo tissue development recited in claim 1, wherein said relationship stimulates growth of said tissue.

11. The apparatus for regulating in vivo tissue development recited in claim 1, wherein said relationship inhibits growth of said tissues.

2716.004

12. An apparatus for the regulation of in vivo tissue development, comprising:
a pair of field coils for generating an applied magnetic flux in a predetermined space and parallel to a predetermined axis which projects through said predetermined space, said predetermined space being occupied by a portion of living tissue of a subject;
a field-sensing device for measuring magnetic flux density parallel to said predetermined axis in said predetermined space;
microprocessing means including means for oscillating said applied magnetic flux in communication with said field coils and said field- sensing device for creating and maintaining a predetermined relationship between the frequency of said magnetic flux and the intensity of said magnetic flux density to provide a fluctuating magnetic field which regulates the development of said living tissue.

13. The apparatus for the regulation of in vivo tissue development recited in claim 12, wherein said field coils are arranged in Helmholtz configuration with respect to said predetermined space.

14. The apparatus for the regulation of in vivo tissue development recited in claim 12, wherein said field-sensing device is a Hall-effect device.

15. The apparatus for the regulation of in vivo tissue development recited in claim 12, further including a first housing of a non magnetic material enclosing one of said field coils and a second housing of non magnetic material enclosing the other of said field coils.

16. The apparatus for the regulation of in vivo tissue development recited in claim 12, further including means attached to said first and second housings for securing said apparatus into position relative to said predetermined space.

17. The apparatus for the regulation of in vivo tissue development recited in claim 12, wherein said predetermined relationship stimulates growth of said tissue 2716.004

18. The apparatus for the regulation of in vivo tissue development recited in claim 12, wherein said predetermined relationship inhibits growth of said tissue.

19. A method for regulating the growth characteristics of tissue in vivo, comprising the steps of:
positioning a magnetic field generating means adjacent to a living subject such that a region of tissue of said subject occupies a predetermined space;
generating a magnetic flux with said magnetic field generating means, said magnetic flux extending through said region of tissue and parallel to a predetermined axis projecting through said predetermined space; and fluctuating said magnetic flux and controlling the density of said magnetic flux to create and maintain a predetermined relationship between the frequency of said fluctuations and the magnitude of said magnetic flux density which regulates development of said tissue.

20. The method for regulating the growth characteristics of tissue in vivo recited in claim 19, wherein said magnetic flux is combined with an ambient magnetic flux present in said region of tissue to create a composite magnetic flux density.

21. The method for regulating the growth characteristics of tissue in vivo recited in claim 19, wherein said predetermined relationship of said frequency to said magnitude of said magnetic flux density is determined using the equation fc/B = q/(2 .pi.m) where fc is said frequency in Hertz, B is the average value of said magnetic flux density in Tesla parallel to said predetermined axis, and q/m has a value of from about 5 x 105 to about 100 x 106 in Coulombs per kilogram and where B preferably has a value not in excess of about 5 x 10-4 Tesla.

22. The method for regulating the growth characteristics of tissue in vivo recited in claim 21, wherein q and m are, respectively, equal to the charge and mass of a preselected ionic species.

23. The method for regulating the growth characteristics of tissue in vivo recited in claim 22 wherein said tissue is bone tissue, said preselected ionic species is Ca++ and said regulation of the development of said tissue is an increase in the rate of tissue growth.

24. The method for regulating the growth characteristics of tissue in vivo recited in claim 22 wherein said tissue is bone tissue, said preselected ionic species is K + and said regulation of the development of said tissue is a decrease in the rate of tissue growth.

25. The method for regulating the growth characteristics of tissue in vivo recited in claim 22 wherein said tissue is bone tissue, said preselected ionic species is Mg++ and said regulation of the development of said tissue is an increase in the rate of tissue growth.

26. A method of applying a magnetic field to a living tissue comprising the steps of:
determining a desired composite magnetic flux having a static field component;
applying a fluctuating magnetic flux to living tissue along an axis;
sensing the actual composite magnetic flux along the desired axis in the living tissue, wherein the actual composite magnetic flux includes a component of the fluctuating applied magnetic flux and a component of a naturally existing static magnetic flux; and comparing the actual composite magnetic flux to the desire composite magnetic flux and modifying the applied magnetic flux such that the actual composite magnetic flux is substantially equal to the desired composite magnetic flux.